WO2019201970A1 - Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t - Google Patents

Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t Download PDF

Info

Publication number
WO2019201970A1
WO2019201970A1 PCT/EP2019/059877 EP2019059877W WO2019201970A1 WO 2019201970 A1 WO2019201970 A1 WO 2019201970A1 EP 2019059877 W EP2019059877 W EP 2019059877W WO 2019201970 A1 WO2019201970 A1 WO 2019201970A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
mertk
ligand
amino acids
lymphocytes
Prior art date
Application number
PCT/EP2019/059877
Other languages
English (en)
Inventor
Per Thor Straten
Marlies Joanne Wilhelmina PEETERS
Original Assignee
University Of Copenhagen
Herlev Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Copenhagen, Herlev Hospital filed Critical University Of Copenhagen
Publication of WO2019201970A1 publication Critical patent/WO2019201970A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/463Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632T-cell receptors [TCR]; antibody T-cell receptor constructs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464454Enzymes
    • A61K39/464462Kinases, e.g. Raf or Src
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases (EC 2.)
    • C12N2501/727Kinases (EC 2.7.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114T cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/30Coculture with; Conditioned medium produced by tumour cells

Definitions

  • the present invention relates to a Mer Tyrosine Kinase (MerTK) ligand for use in adoptive T cell transfer cancer therapy in an individual.
  • MerTK Mer Tyrosine Kinase
  • Cancer immunotherapy may be divided into three major categories: non-specific stimulation of the immune system, active immunization using cancer vaccines, and adoptive cell transfer immunotherapy.
  • Adoptive cell transfer is based on transfer of immune cells with anti-tumor activity into cancer patients.
  • T cells are generally divided into CD4 and CD8 T cells.
  • CD4 T cells are functionally plastic and may possess helper function for CD8 T cells, but may also differentiate into regulatory T cells which suppress CD8 T cell responses.
  • CD8 T cells are less plastic and this cell type has as its main function to kill cells - be it infected cells (e.g., with virus) or cancer cells.
  • T cells used for ACT can be derived from tumor tissue (tumor infiltrating lymphocytes or TILs). TILs comprise relatively high frequencies of tumor specific T cells which can be expanded in vitro and transferred back to the patient in what is called“TIL based ACT” therapy. Blood T cells can also be used for harvest of cells. For treatment of cancer, tumor specific T cells are, however, scarce in blood, but T cells harvested from blood may be genetically engineered to express T cell receptors (TCRs) that recognize human leukocyte antigen (HLA)/peptide complexes expressed by cancer cells, or chimeric antigen receptors (CARs) which equip the cells with antibody recognition capacity, i.e., unleash the killing capacity based on expression of a molecule expressed on the cell surface.
  • TCRs T cell receptors
  • HLA human leukocyte antigen
  • CARs chimeric antigen receptors
  • CD4 T cells may play a role in ACT.
  • ACT a mutated antigen
  • CD8 T cells are the main cell types associated with clinical response in ACT therapy.
  • TIL based ACT in melanoma CD8 frequency in administered TIL cultures is associated with clinical response (Andersen et al. 2016, Rosenberg et al. 2011 ).
  • CD8 act as a co-stimulatory molecule to HLA class I which is expressed by all nucleated cells including cancer cells
  • CD4 is a co-receptor for HLA class II molecules which is only expressed by antigen presenting cells.
  • gd T cells expressing a gd T cell receptor
  • invariant chain T cells which express a TCR with limited heterogeneity
  • NK T cells - expressing a T cell receptor along with more NK cell recognition and killing features - could potentially be exploited in ACT.
  • ACT based on the killing capacity of CD8 T cells is by far the most mature and clinically validated.
  • Mer Tyrosine Kinase is a member of the TAM family of receptor kinases which consists of Tyro3, Axl, and Mer. Best described ligands for TAM are are growth arrest- specific protein (Gas6) and Protein S (Prosl ). Gas6 is a ligand for all three TAMs whereas Prosl is a ligand for Tyro and MerTK only.
  • Cabezon et al. 2015 disclose expression of MerTK and Prosl in activated CD4 T cells and that addition of Prosl to activated CD4 T cell cultures induces proliferation and cytokine production.
  • the present inventors have surprisingly found that CD8+ T lymphocytes express MerTK and Prosl and that stimulation of these cells with a MerTK ligand, such as Prosl , leads to increased proliferation and pro-inflammatory cytokine release.
  • a MerTK ligand such as Prosl
  • the present inventors propose an improved method for adoptive T cell transfer cancer therapy wherein T cells are stimulated by a MerTK ligand thereby increasing their tumor reactivity.
  • the present disclosure relates to a Mer Tyrosine Kinase (MerTK) ligand for use in a method of adoptive cell transfer cancer therapy in an individual.
  • the method may be performed by the following steps:
  • Mer Tyrosine Kinase also referred to as c-mer, Mer, MER, Proto-oncogene c-Mer, Receptor Tyrosine Kinase MerTK, Tyrosine-protein Kinase Mer, STK Kinase, RP38, or MGC133349
  • MME133349 is a member of the TAM family of receptor tyrosine kinases, which also include AXL and TYR03 kinases.
  • MerTK transduces signals from the extracellular space via activation by binding of ligands, most notably Gas-6, a soluble protein and Prosl .
  • ligands most notably Gas-6, a soluble protein and Prosl .
  • Three other TAM ligands have recently been described: Galectin-3, Tubby, and Tulp-1.
  • CD8+ T lymphocytes kill target cells expressing the cognate antigenic peptide target.
  • the term“CD8 T cells” or“CD8+ T lymphocytes” as used interchangeably herein refers to conventional CD8 positive Hla class I restricted T lymphocytes of the adaptive immune system. Memory T cells are a subset of T cells that have previously encountered and responded to their cognate antigen. These cells are long lived.
  • TCM refers to T central memory cells.
  • TILs Tumor infiltrating lymphocytes
  • TILs are white blood cells that have left the bloodstream and migrated into a tumor.
  • ACT Adoptive cell therapy, abbreviated ACT is herein used interchangeably with the term adoptive cell transfer.
  • ACT involves the transfer of immune cells with antitumor activity into cancer patients.
  • ACT is a treatment approach that usually involves the
  • Autologous a situation in which the donor and recipient of e.g. lymphocytes are the same person.
  • Heterologous a situation in which the donor and recipient of e.g. lymphocytes are not the same person.
  • Cytokines are small, secreted polypeptides from higher eukaryotes which are responsible for intercellular signal transduction and which affect the proliferation, division and functions of other cells. They are potent, pleiotropic polypeptides that, e.g. via corresponding receptors, act as local or systemic intercellular regulatory factors, and therefore play crucial roles in many biologic processes, such as immunity, inflammation, and hematopoiesis. Cytokines are produced by diverse cell types including fibroblasts, endothelial cells, epithelial cells, macrophages/monocytes, and lymphocytes.)
  • Interleukins are a group of cytokines important for the function of the immune system.
  • Pro-inflammatory refers to an agent capable of promoting inflammation.
  • Pro-inflammatory cytokines include TNF-a, IFN-g and lnterleukin-2 (IL-2). Description of Drawings
  • FIG. 1 MerTK receptor and ligand PROS1 are expressed by TCR-activated human CD8+ T cells.
  • Human CD8+ T cells were negatively isolated from peripheral blood mononuclear cells (PBMCs) and activated with aCD3/CD28 beads.
  • A Representative histogram of
  • F Representative histogram of (E).
  • G MerTK protein expression (top) on day 3 of activation of PBMCs or CD8+ T cells, as analysed by western blot (representative of at least 3 independent experiments) b-actin (bottom) served as a loading control. Data are plotted as mean ⁇ SEM. *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
  • PROS1 positively regulates CD8+ T cell proliferation.
  • (B) Relative proliferation, with aCD3/CD28 activated CD8+ T cells set as 100, of activated CD8+ T cells cultured for 3 days in the presence or absence of 50 nM PROS1 (n 4).
  • (C) IFN-g and (D) TNF-a production in culture supernatants (n 3).
  • F Representative histogram of (E). Data are plotted as mean ⁇ SEM. *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
  • PROS1 impacts on human melanoma TIL expansion.
  • TILs from 4 metastatic melanoma patients were isolated, cultured and expanded according to the clinical Rapid Expansion Protocol (REP, with human serum-containing medium, 6000U/ml IL-2, and feeder cells) in the presence or absence of 50 nM PROS1 or aPROS1 mAb.
  • the figure represents a schematic representation of domains in Gas6 and Prosl .
  • the domains predicted to be involved in TAM binding are the laminin G-like domains 1 and 2.
  • CM central-memory
  • EM effector-memory
  • TEMRA terminally differentiated EM cells. Data are plotted as mean ⁇ SEM and statistical significance was determined with Student’s t tests or two- way ANOVA with Bonferroni’s multiple comparisons tests. *p ⁇ 0.05, **p ⁇ 0.01 ,
  • MERTK is expressed by naturally occurring activated peripheral CD8+ T cells.
  • CD137+ T cells (CD137+) T cells.
  • C Representative histogram of MERTK on CD137- and CD137+ CD8+ T cells.
  • MERTK acts as a co-stimulatory molecule on CD8+ T cells.
  • siRNA-mediated knockdown (compared to control) of MERTK on three-day CD3/CD28-stimulated CD8+ T cells, followed for 24, 48 and 72h after siRNA knockdown as analyzed by MERTK protein expression via westernblot (representative of at least 3 independent experiments) b-actin (bottom) served as a loading control.
  • C) Cytokine concentrations (IFN-g, IL-2, IL-7, IL-15) in supernatants of MERTK-knockdown and control CD8+ T cells re-stimulated overnight with aCD3/CD28, 48 hours after siRNA knockdown (n 4).
  • D) Human CD8+ T cells were cultured in serum-free medium, stained with a proliferation dye and activated for three days with aCD3/CD28 in the presence or absence of 250 nM MERTK-inhibitor UNC2025. Proliferation was measured by flow cytometry and relative proliferation was calculated compared to control (n 3).
  • TILs Tumor infiltrating lymphocytes
  • CM central-memory
  • EM effector-memory
  • TEMRA terminally differentiated EM cells.
  • C TAM receptor protein expression status of tumor cells from 3 metastatic melanoma patients.
  • Actin was used a loading control.
  • D Real- time in vitro cytolysis of autologous cancer cells from metastatic melanoma patient 3 after addition of antigen-selected autologous TILs (1 :10 or 1 :20 targeheffector ratio).
  • E % Cytolysis 48 hours post TIL addition. Data are plotted as mean ⁇ SEM and statistical significance was determined with two-way AN OVA with Bonferroni’s multiple comparisons tests (A). *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
  • Figure 10 Blocking PROS1 -MERTK axis decreases mitochondrial respiration in CD8+ T cells.
  • Basal respiration was determined as initial resting consumption of oxygen.
  • B ATP turnover was measured as decrease of oxygen consumption after addition of oligomycin.
  • C Reserve respiratory capacity was measured as percentage of basal respiration, after addition of Carbonyl cyanide-4- (trifluoromethoxy)phenylhydrazone (FCCP).
  • D Glycolytic capacity was measured after addition of oligomycin.
  • E Raw levels of oxygen consumption. Cells were treated with either oligomycin or FCCP at stage A and antimycin A at stage B.
  • F Whole-cells levels of ATP normalized to control. Data are plotted as mean ⁇ SEM and statistical significance was determined with Student’s t tests (A,B,C,D,F). *p ⁇ 0.05, **p ⁇ 0.01 , ***p ⁇ 0.001.
  • Blocking PROS1 -MERTK axis decreases mitochondrial respiration in CD8+ T cells.
  • Nanostring-measured IRF4 mRNA expression in three-day activated CD8+ T cells analyzed as in Figure 8.
  • PROS1 impacts on anti-tumor tumor-infiltrating lymphocytes.
  • A Representative dot plots of PROS1 and MERTK co-staining on CD8+ T cells, activated for 3 days with aCD3/CD28 in the presence or absence of 5 mg/ml unconjugated Annexin V.
  • SEQ ID NO: 1 is the full length Prosl polypeptide having the following sequence:
  • SEQ ID NO: 2 is a fragment of Prosl and comprises an alternative predicted sequence of the LG-like binding domain 1 known to be involved in MerTK binding and
  • SEQ ID NO: 3 is a fragment of Prosl and comprises an alternative predicted sequence of the LG-like binding domain 2 known to be involved in MerTK binding and
  • SEQ ID NO: 4 is fragment of Prosl and comprises a predicted sequence of the LG-like binding domain 1 as shown in fig 4 and corresponds to amino acids 299-475 of SEQ ID NO: 1 :
  • SEQ ID NO: 5 is a fragment of Prosl and comprises a predicted sequence of the LG- like binding domain 2 as shown in fig. 4 and corresponds to amino acids 484-666 of SEQ ID NO: 1 :
  • SEQ ID NO: 6 is a fragment of Prosl and comprises a predicted sequence comprising the LG-like binding domains 1 and 2 as shown in fig. 4 and corresponds to amino acids 299-666 of SEQ ID NO: 1 :
  • SEQ ID NO: 7 is a fragment of Prosl and comprises a predicted sequence comprising the LG-like binding domains 1 and 2 and corresponds to amino acids 329-647 of SEQ ID NO: 1 :
  • SEQ ID NO: 8 is fragment of Prosl and comprises amino acids predicted to be involved in binding to MerTK and corresponds to amino acids 42-666 of SEQ ID NO:1 :
  • the present disclosure provides a method for improving the clinical efficacy of ACT by using T lymphocytes which have been stimulated with a MerTK ligand.
  • the present disclosure relates to a Mer Tyrosine Kinase (MerTK) ligand for use in a method of adoptive cell transfer cancer therapy in an individual comprising the consecutive steps of
  • the present disclosure relates to in vitro method of stimulating CD8+ T lymphocyte proliferation and/or cytokine release comprising the steps of
  • said method further comprises administering a therapeutically effective amount of a MerTK ligand, such as Prosl to said individual.
  • the MerTK ligand maybe be administered once a week, for example twice a week, such as three times a week, for example four times a week, such as five times a week, for example six times a week, such as daily or for example monthly.
  • the MerTK ligand such as Prosl
  • the MerTK ligand can e.g. be administered throughout treatment of said individual, i.e. until the tumour has regressed/decreased and/or until amelioration of symptoms and/or until said individual is cured.
  • the MerTK ligand may be administered prior to, simultaneously with or after the T lymphocytes to said individual.
  • T lymphocytes The stimulation of T lymphocytes with the MerTK ligand is believed to stimulate tumor cell immunogenicity, thereby augmenting tumor reactivity of T lymphocytes.
  • An increase in T lymphocyte reactivity will result in enhanced efficacy of adoptive cell therapy (ACT).
  • ACT adoptive cell therapy
  • ACT involves the transfer of lymphocytes with anti-tumor activity into cancer patients.
  • ACT is a treatment approach that usually involves the identification, in vitro, of lymphocytes with anti-tumor activity, the in vitro expansion of these cells to large numbers and their infusion into the cancer-bearing host.
  • Lymphocytes used for adoptive transfer can either be derived from the stroma of resected tumors (tumor infiltrating lymphocytes or TILs), or from blood: genetically engineered to express anti- tumor T cell receptors (TCRs) or chimeric antigen receptors (CARs) as described previously by Rosenberg (Rosenberg et al., 2011 ); enriched with mixed lymphocyte tumor cell cultures (MLTCs) as described by Mazzarella (Mazzarella et al., 2012) or cloned using autologous antigen presenting cells and tumor derived peptides as described by Yee (Yee et al., 2002).
  • TCRs tumor T cell receptors
  • CARs chimeric antigen receptors
  • the lymphocytes used for infusion can be isolated from a donor, or from the cancer-bearing host itself.
  • ACT in which the lymphocytes originate from the cancer-bearing host to be infused is termed autologous ACT.
  • ACT in which the lymphocytes originate from a donor to be infused is termed heterologous ACT.
  • ACT may be performed by (i) obtaining lymphocytes from an individual, (ii) culturing said lymphocytes with a MerTK ligand, and (iii) administering the expanded lymphocytes to the individual.
  • the lymphocytes are usually expanded prior to administration to the individual.
  • the lymphocytes are tumor-derived, i.e. they are TILs, and are isolated from the individual to be treated, i.e. autologous transfer.
  • the cancer therapy comprises heterologous adoptive cell therapy of T lymphocytes.
  • the MerTK ligand as described herein is capable of activating MerTK signalling and of stimulating proliferation and/or cytokine release of T cells.
  • the ligand that specifically binds to MerTK is selected from the group of Prosl , Gas6, Galectin-3, Tubby and Tulp-1 , or active fragments, variants or variants of fragments thereof.
  • the MerTK ligand is a Prosl polypeptide, which may be full length Prosl , an active variant of Prosl , a fragment of Pros 1 or a variant of a fragment of Prosl .
  • the MerTK ligand is a Prosl polypeptide in the form of a fragment or variant of full length Prosl (SEQ ID NO: 1 ) comprising the amino acid residues which are involved in binding of Prosl to MerTK.
  • the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence according to SEQ ID NO: 2 and/or SEQ ID NO: 3.
  • SEQ ID NO: 2 and SEQ ID NO: 3 are predicted sequences of LG-like domains 1 and 2 and have been predicted to be involved in Prosl binding to MerTK.
  • the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence according to SEQ ID NO: 4 and/or SEQ ID NO: 5.
  • SEQ ID NO: 4 and SEQ ID NO: 5 are predicted sequences of LG-like domains 1 and 2 (as shown in fig. 4) and have been predicted to be involved in Prosl binding to MerTK.
  • the MerTK ligand is a Prosl polypeptide comprising a variant of SEQ ID NO: 2 and/or SEQ ID NO: 3 having at least 80% sequence identity to said sequences, such as least 85% sequence identity to said sequences, for example at least 90% sequence identity to said sequences, such as at least 95% sequence identity to said sequences, for example at least 97% sequence identity to said sequences.
  • sequence identity is at least 90%.
  • the MerTK ligand is a Prosl polypeptide comprising a variant of SEQ ID NO: 4 and/or SEQ ID NO: 5 having at least 80% sequence identity to said sequences, such as least 85% sequence identity to said sequences, for example at least 90% sequence identity to said sequences, such as at least 95% sequence identity to said sequences, for example at least 97% sequence identity to said sequences.
  • sequence identity is at least 90%.
  • the MerTK ligand is a Prosl polypeptide comprising SEQ ID NO: 6 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
  • sequence identity is at least 90%.
  • the MerTK ligand is a Prosl polypeptide comprising SEQ ID NO: 7 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
  • sequence identity is at least 90%.
  • the MerTK ligand is a Prosl polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 1 , such as least 85% sequence identity to SEQ ID NO: 1 , for example at least 90% sequence identity to SEQ ID NO: 1 , such as at least 95% sequence identity to SEQ ID NO: 1 , for example at least 97% sequence identity to SEQ ID NO: 1 , or a fragment thereof comprising at least 150 amino acids, such as at least 200 amino acids, for example at least 250 amino acids, such as at least 300 amino acids, for example at least 350 amino acids, such as at least 400 amino acids, for example at least 450 amino acids, such as at least 500 amino acids, for example at least 550 amino acids, such as at least 600 amino acids, for example at least 650 amino acids.
  • the MerTK ligand is a Prosl polypeptide comprising or consisting of SEQ ID NO: 8 or a fragment or variant thereof.
  • SEQ ID NO: 1 comprises amino acid residues which are involved in binding of Prosl to MerTK.
  • the Prosl polypeptide comprises SEQ ID NO: 8 or a variant thereof having at least 80% sequence identity to said sequence, such as least 85% sequence identity to said sequence, for example at least 90% sequence identity to said sequence, such as at least 95% sequence identity to said sequence, for example at least 97% sequence identity to said sequence.
  • the sequence identity is at least 90%.
  • the MerTK ligand is a polypeptide, such as a Prosl polypeptide comprising less than 700 amino acids, such as less than 650 amino acids, for example less than 600 amino acids, such as less than 550 amino acids, for example less than 500 amino acids, such as less than 450 amino acids, for example less than 400 amino acids, such as less than 350 amino acids, for example less than 300 amino acids, such as less than 250 amino acids, for example less than 200 amino acids, such as less than 150 amino acids.
  • a polypeptide such as a Prosl polypeptide comprising less than 700 amino acids, such as less than 650 amino acids, for example less than 600 amino acids, such as less than 550 amino acids, for example less than 500 amino acids, such as less than 450 amino acids, for example less than 400 amino acids, such as less than 350 amino acids, for example less than 300 amino acids, such as less than 250 amino acids, for example less than 200 amino acids, such as less than 150 amino acids.
  • the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 500 amino acids.
  • the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 300 amino acids.
  • the MerTK ligand is a polypeptide, such as a Prosl polypeptide, comprising less than 150 amino acids.
  • the MerTK ligand is a polypeptide, such as a Prosl polypeptide comprising at least 100 amino acids, such as at least 150 amino acids, for example at least 200 amino acids, such as at least 250 amino acids, for example at least 300 amino acids, such as at least 350 amino acids, for example at least 400 amino acids, such as at least 450 amino acids, for example at least 500 amino acids, such as at least 550 amino acids, for example at least 600 amino acids, such as at least 650 amino acids.
  • the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 100 amino acids.
  • the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 300 amino acids.
  • the MerTK ligand is a polypeptide, such as a Pros1 polypeptide comprising at least 500 amino acids.
  • the MerTK ligand is a Gas6 polypeptide, which may be full length Gas6, an active variant of Gas6, a fragment of Gas6 or a variant of a fragment of Gas6.
  • the MerTK ligand is provided in an amount capable of activating MerTK.
  • the MerTK ligand is provided in the amount between about 10nM to about 1000nM, for example about 10nM to about 900 nM, such as about 10nM to about 800nM, for example about 10nM to about 700nM, such as about 10nM to about 600nM, for example about 10nM to about 500nM, such as about 10nM to about 400nM, for example about 10nM to about 300nM, such as about 10nM to about 200nM, for example about 10nM to about 100nM, for example about 50nM.
  • the MerTK ligand is provided in the amount between about 10nM to about 100nM, for example about 10nM to about 90nM, such as about 10nM to about 80nM, for example about 10nM to about 70nM, such as about 10nM to about 60nM, for example about 10nM to about 50nM, such as about 10nM to about 40nM, for example about 10nM to about 30nM, such as about 10nM to about 20nM.
  • the MerTK ligand promotes the proliferation and cytokine production by CD8+ T cells.
  • the ability of CD8 T cells to proliferate and produce cytokines plays an important role in the capacity of such T cells to control tumor progression.
  • the MerTK ligand promotes the secretion of pro-inflammatory cytokines by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of interleukins by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of interferons such as IFNy by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of TNFa by CD8+ T cells. In yet another embodiment, the MerTK ligand promotes the secretion of IL-2 by CD8+ T cells.
  • the MerTK ligand upregulates IRF4 expression.
  • the term upregulates used herein is to be understood as an increase in the quantity of a cellular component, such as RNA or protein in response to the said MerTK ligand stimulation.
  • an antibody capable of stimulating MerTK signalling for use as a MerTK ligand.
  • Antibodies that specifically bind to human Mer Tyrosine Kinase (MerTK) capable of stimulating MerTK signalling are described in, e.g., WO2016106221 , which is incorporated herein by reference in its entirety.
  • TILs may be obtained from the stroma of resected tumors. Tumor samples are obtained from patients and a single cell suspension is obtained. The single cell suspension can be obtained in any suitable manner, e.g., mechanically (disaggregating the tumor using, e.g., a gentleMACS (TM) Dissociator, Miltenyi Biotec, Auburn, Calif.) or enzymatically (e.g., collagenase or DNase). Alternatively, T cells may be grown from tumor pieces by IL-2 and MerTK ligand with or without activating CD3 antibody
  • the population of T lymphocytes Prior to administration of the MerTK ligand, the population of T lymphocytes is stimulated by an agent capable of stimulating MerTK expression.
  • the agent is selected from the group consisting of activating CD3 antibody, activating CD28 antibody, IL-2 and combinations thereof.
  • the population of T lymphocytes comprises or consists essentially of CD8+ T lymphocytes.
  • the CD8+ T cells comprise effector T lymphocytes expressing CD8.
  • the T lymphocytes are usually conventional CD8 positive Hla class I restricted T cells of the adaptive immune system, expressing variant ab T cell receptors.
  • the population of T lymphocytes does not comprise or consist essentially of cells selected from the group of NKT cells, CD4+ T lymphocytes and T regulatory lymphocytes.
  • the population of lymphocytes comprises memory T cells. In one embodiment, the population of lymphocytes comprises effector T cells and memory T cells.
  • the T lymphocytes used in the adoptive T cell cancer therapy according to the present disclosure are TILs.
  • the population of T lymphocytes comprises or consists essentially of TILs.
  • lymphocytes to expand the number of lymphocytes, including tumor- infiltrating lymphocytes, such as T cells
  • T cells can be accomplished by any of a number of methods as are known in the art.
  • T cells can be rapidly expanded using non-specific T-cell receptor stimulation in the presence of feeder lymphocytes and interleukin-2 (IL-2), IL-7, IL-15 and IL-21 , with IL-2 being preferred.
  • IL-2 interleukin-2
  • IL-7 interleukin-7
  • IL-15 interleukin-21
  • T cells for use according to the ACT methods described herein can also be obtained from blood, lymphoid tissue (e.g. spleen) or from a tumor (e.g. tumor infiltrating lymphocytes).
  • T cells for use according to the ACT methods described herein are produced from PBMCs that have a histocompatible phenotype to the subject with cancer to be treated. These PBMCs are thus heterologous to the subject with cancer to be treated. In related embodiments, the PBMCs are autologous to the subject with cancer to be treated.
  • the T cells are genetically engineered to express T cell receptors (TCRs) that recognize human leukocyte antigen (HLA)/peptide complexes expressed by cancer cells or chimeric antigen receptors (CARs) of the individual to be treated.
  • TCRs T cell receptors
  • HLA human leukocyte antigen
  • CARs chimeric antigen receptors
  • the T lymphocytes have been cultured for between about 14 to about 40 days prior to administration to the individual. In one embodiment, the T lymphocytes have been cultured for about 19 to about 35 days prior to administration to the individual. In other embodiments of the disclosure, the administered lymphocytes have been cultured for less than 14 days and in yet other embodiments, the lymphocytes have been cultured for longer than 40 days prior to administration to the individual.
  • the lymphocytes can be administered by any suitable route known in the art.
  • the lymphocytes are administered as an intra-arterial or intravenous infusion, which may last about 30 to about 60 minutes.
  • routes of administration include intraperitoneal, intrathecal and intralymphatic.
  • lymphocytes can be administered.
  • about 1 x 10 4 lymphocytes to about 1 x 10 10 lymphocytes are provided.
  • x 10 5 lymphocytes to about 1 x 10 9 lymphocytes such as about 1 x 10 5 lymphocytes to about 1 x 10 8 lymphocytes, such as about 1 x 10 5 lymphocytes to about 1 x 10 7 lymphocytes, for example about 1 x 10 5 lymphocytes to about 1 x 10 6 lymphocytes, such as about 1 x 10 5 lymphocytes to about 9 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 8 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 7 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 6 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 5 x 10 5 lymphocytes, for example about 1 x 10 5 lymphocytes to about 4 x 10 5 lymphocytes, such as about 1 x 10 5 lymphocytes to about 3 x 10 5 lymphocytes, for example about 2 x 10 5 lymphocytes
  • the T lymphocytes may be administered one or more times to the individual.
  • Inhibition of Prosl was shown to increase the expression of the genes selected from the group consisting of LTA, TNFSRF9, IL-2, and IFN-g. Inhibition of Prosl was shown to decrease the expression of the genes selected from the group consisting of IL4R, DUSP4, CD99, ITGAL and CCL5.
  • the cancer to be treated by the methods of the present disclosure can be any cancer that is likely to benefit from ACT, including any of acute lymphocytic leukaemia, acute myeloid leukaemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the vulva, chronic lymphocytic leukaemia, chronic myeloid cancer, cervical cancer, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, ovarian cancer,
  • the cancer can be a recurrent cancer.
  • the cancer is a solid cancer.
  • the cancer is selected from melanoma, ovarian, breast and colorectal cancer.
  • the cancer is a cancer of the hematopoietic or lymphoid system.
  • the cancer is melanoma, such as cutaneous metastatic melanoma.
  • the individual to be treated according to the methods described herein may be any subject likely to benefit from ACT.
  • the individual is usually a mammal, preferably a human.
  • mammal refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Lagomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order
  • Perssodactyla including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids
  • CD8 T cells used in ACT are not stimulated with a MerTK ligand but rather express a constitutive active MerTK, thus allowing for constitutive MerTK signalling without ligand stimulation.
  • CD8 T cells can e.g. be isolated from tumor tissue, i.e. TILs, or CD8 T cells from blood samples can be rendered tumor specific by genetic modification e.g. by forced introduction, e.g., by viral transduction with a vector expressing a receptor that recognize cancer cells, e.g., a T cell receptor (TCR), or a chimeric antigen receptor (CAR).
  • TILs tumor tissue
  • CD8 T cells from blood samples can be rendered tumor specific by genetic modification e.g. by forced introduction, e.g., by viral transduction with a vector expressing a receptor that recognize cancer cells, e.g., a T cell receptor (TCR), or a chimeric antigen receptor (CAR).
  • TCR T cell receptor
  • CAR chimeric antigen receptor
  • Such tumor specific T cells can be further manipulated to express a constitutively active form of MerTK, e.g. as described previously by Kasikara et al., e.g, by viral transduction, in turn leading to T cells having improved cytokine production and proliferation and ultimately improved effect in ACT.
  • MerTK constitutively active form of MerTK
  • the present disclosure provides a CD8+ T lymphocyte genetically modified to express a constitutive active MerTK.
  • the CD8+ T lymphocyte genetically modified to express a constitutive active MerTK may in turn be used in a method of ACT cancer therapy.
  • the present disclosure is further described by the following examples that should not be construed as limiting the scope of the disclosure.
  • Biopsies from patients with stage III or IV melanoma was collected from 2006- 2013, and used for expansion of tumor infiltrating lymphocytes (TIL).
  • Biopsy material was cut into small fragments (1-2 mm2) and kept overnight (ON) in a humidified 37°C CO 2 incubator. The following day, tumor fragments and cells were resuspended, washed twice in 1xPBS (Lonza) by centrifugation for 5 minutes at 1500 RPM and cryopreserved in fetal bovine serum (FBS, Gibco) + 10% DMSO (Sigma Aldrich). All biopsies originated from lymph nodes LN metastases removed under palliative surgery. Antibodies and reagents
  • anti-CD3 clone UCHT1
  • anti-CD8 RPA-T8
  • anti-CD45RO UCHL-1 , all BD Biosciences
  • anti-CD4 SK3
  • anti-CCR7 G043H7, all Biolegend
  • anti-PROS1 PS7, Santa Cruz Biotechnologies
  • anti-MerTK anti-Tyro3
  • anti-Axl 108724, all R&D Systems
  • TIL tumor infiltrating lymphocytes
  • Cell suspensions were thawn and placed in 24 well-culture plates (Nunc, Roskilde, Denmark) together with 2 ml of culture medium (90% RPMI 1640 (Invitrogen), 10% heat inactivated Human AB serum (Sigma-Albricht, USA), IL-2 6000 lU/ml (6000 lU/ml IL-2, Proleukin, Novartis), penicillin, streptomycin and fungi zone (Bristol-Myers Squibb, Lyngby, Denmark). Cells were split into 2-3 wells when cell concentration in 1 well exceeded 1.5 x 106 cells/ml.
  • culture medium 90% RPMI 1640 (Invitrogen), 10% heat inactivated Human AB serum (Sigma-Albricht, USA), IL-2 6000 lU/ml (6000 lU/ml IL-2, Proleukin, Novartis), penicillin, streptomycin and fungi zone (Bristol-Myers Squibb, Lyngby, Denmark
  • Expansions were set up in culture triplicates plus Prosl (50 nM PROS1 (Hematologic Technologies)), plus mAb Prosl (10 mg/ml, clone PS7, Santa Cruz Biotechnologies) , and control expansions. Outgrowth of T cells measured by counting of live CD3 positive T cells, and fold expansion was calculated.
  • ELISA was used to study levels of IFN-g and TNF-a (ELISA Ready-Set-Go kits,
  • CD3/CD28 bead stimulated T cell cultures upon addition of prosl or aProsl mAb.
  • CD3/CD28 bead stimulated T cell cultures were studied upon siRNA gene knock down. Culture supernatants were tested at different dilutions following the manufacturer’s protocol.
  • Human CD8+ T cells were isolated from human PBMCs by negative selection using MagniSortTM Human CD8 T cell Enrichment Kit, according to the manufacturer’s instructions (Thermo Fisher Scientific). Purified total CD8 T cells, or for some experiments total PBMCs, were cultured in the presence (1 :1 ratio) or absence of anti- human CD3/CD28 coated Dynabeads (Thermo Fisher Scientific) in X-VIVO 15 medium (Lonza), supplemented with 5% human serum and 50 U/ml hlL-2 for 1 to 7 days. To evaluate PROS1 and TAM receptor expression, cells were harvested daily (for surface expression) or after 3 days (for RT-qPCR).
  • cells were cultured in serum free medium in the presence or absence of 50 nM PROS1 (Hematologic Technologies) and cells were harvested for analysis after 3 days of activation.
  • PROS1 blocking experiments cells were cultured in medium with 5% human serum for 3-5 days prior to analysis, in the presence or absence of anti-PROS1 (clone PS7, Santa Cruz
  • Membranes were incubated with primary antibodies (rabbit anti-human MERTK (D21 F11 , Cell Signalling), at 4°C overnight in TBS-T with 5% BSA and reprobed with mouse anti-human actin (C4, SCBT)). After several washing steps and incubation with HRP-linked secondary antibodies (Cell Signalling), proteins were detected using SuperSignal West ECL Kit and BioRad Analyzer. Quantification of signal was done using Fiji ImageJ (v.1.49).
  • RNA isolation was done using the NucleoSpin® RNA kit (Cat# 740955.50, MACHEREY-NAGEL, Düren, Germany) kit according to manufacturer’s instructions.
  • RNA was reverse-transcribed to cDNA using Superscript® VI LOTM cDNA Synthesis Kit (Invitrogen, Thermo Fisher Scientific, Cat# 11754-050).
  • qPCR was performed in Agilent AriaMX System using the Brilliant III Ultra- Fast QPCR Master Mix (Agilent). Amplified products were checked by dissociation curves and expression was normalized to housekeeping genes.
  • a set of three Stealth siRNA duplexes for targeted silencing of human MERTK were obtained from Invitrogen.
  • three siRNAs with scrambled sequences possessing similar GC content were used.
  • three-day stimulated CD8+ T cells were transfected with MERTK or Mock siRNA with the ECM830 square wave electroporation system (BTX) using electroporation parameters as previously described. Knockdown on protein level was confirmed for every individual experiment.
  • BTX square wave electroporation system
  • TILs The tumor-specific killing ability of TILs was assessed with a novel impedance-based cytotoxicity assay. Briefly, antigen-specific TILs were thawed and rested in IL-2 free media (RPMI 1640 supplemented with 10% human serum, penicillin and streptomycin) for 72 hours. Autologous tumor cells were seeded on E-plate 96 plates (ACEA Biosciences Inc) which were loaded onto RTCA SP real-time cell analyzer (ACEA Biosciences Inc). After 24 hours, TILs were added with or without 50 nM PROS1.
  • IL-2 free media RPMI 1640 supplemented with 10% human serum, penicillin and streptomycin
  • RNA and protein samples were split and processed separately. Transcriptomic analysis was performed using the nCounter Vantage 3D RNA:Protein Immune Cell Signaling Panel. Samples were subsequently processed in the fully automated nCounter Prepstation (NanoString Technologies) and analyzed in the nCounter Digital Analyzer (NanoString Technologies).
  • nSolver4 software (NanoString Technologies) was used for data normalization and differential gene expression analyses.
  • the significance of differential gene expression between paired groups was estimated using a mixed module significance testing with the algorithm included in the nCounter Advanced Analysis. In this module, a negative binomical mixture model for low expression probes or a simplified negative binomial model for high expression probes was used. Differential expression is indicated as the log2 fold change in gene or protein expression and the obtained p-values were adjusted for multiple testing by the Benjamini and Hochberg method (BH. p-value) to control the false discovery rate. Differentially expressed genes and proteins were depicted as volcano plot using R/RStudio v1.0.44.
  • the bioenergetics from CD8+ T cells were measured in the presence or absence of co- stimulatory MERTK signalling in real-time using an XF-96 Extracellular Flux Analyzer.
  • aCD3/CD28 stimulated CD8+ T cells were grown in the presence or absence of 50 nM PROS1 (serum free medium) or aPROS1 (10 mg/ml, serum-containing medium) for three days prior to use.
  • Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) were measured where after wells were treated with 1 mM oligomycin and 10 mM 2-deoxy-D- glucose to measure ATP turnover and glycolytic capacity from the changes in OCR and ECAR respectively, or with 0.4 pM carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP) to determine reserve respiratory capacity from change in OCR. All wells received a final treatment with 2mM Antimycin A.
  • Expansion conditions included culture medium in the presence or absence of 50 nM PROS1 or 10 mg/ml aPROS1. Outgrowth of‘young’ TILs was measured by manual, unblinded counting of live cells and fold expansion was calculated.
  • TILs designated for in vitro killing assays were isolated and expanded in vitro from metastatic melanoma lesions with a two-step process as described previously (52). Expanded TILs with high specificity for the HLA-A2 restricted MART-1 /MelanA peptide analogue ELAGIGILTV (>90% specific with peptide-MHC multimer staining) were obtained through electronic sorting of relevant CD8+‘young’ TILs, using peptide-MHC multimers. TILs were subsequently subjected to the rapid expansion protocol, as previously described.
  • cells were cultured in medium with 5% human serum with aPROS1 (10 mg/ml) or unconjugated Annexin V (5 mg/ml), respectively.
  • High TAM receptor-expressing MDA-MB-231 cell line was cultured in serum-free X-VIVO medium for 1 week prior to co-culture. Subsequently, MDA-MB-231 cells were plated in a flat-bottom 96-well plate and left to adhere for approximately 4 hours. Sorted allogenic non-reactive CD8+ T cells and aCD3/CD28 beads were added in a 1 :10 tumor cell:T cell ratio. A PROS1 titration was added in the range of 0-100 nM PROS1. After 4 days of co-culture, supernatants were harvested and analyzed by ELISA. Example 1. MerTK receptor and ligand PROS1 are expressed by TCR-activated human CD8+ T cells.
  • T cells was evaluated by RT-qPCR.
  • MerTK protein expression was analysed on day 3 of activation of PBMCs or CD8+ T cells, as analysed by western blot.
  • the results are shown in fig. 1.
  • Example 2 Positive regulates CD8+ T cell proliferation.
  • Human CD8+ T cells were cultured in serum-free medium, stained with a proliferation dye (CTV, Cell Trace Violet), and activated for 3 days with aCD3/CD28 in the presence or absence of 50 nM PROS1. Proliferation was measured by flow cytometry and IFN-g as well as TNF-a production was measured in culture supernatants.
  • CTV Cell Trace Violet
  • Example 3 PROS1 impacts on human melanoma TIL expansion.
  • TAM signalling in CD8 T cells represent an important co- stimulatory immune checkpoint. Since both cancer cells and activated T cells express ligands for Prosl , we hypothesize that the TAM axis plays a role in suppressing T cell functionality upon interaction with cancer cells: We propose that cancer cells through upregulated expression of TAMs compete for stimulatory Prosl secreted by T cells, by which cancer cells acquire a dual advantage; prevent the stimulatory TAM signalling in the T cell, and at the same time augment intrinsic oncogenic TAM signalling.
  • this strategy for T cell suppression would potentially inflict on all T cells interacting with cancer cells in the microenvironment, not just T cells expressing individual inhibitory immune check point molecules, e.g., PD-1.
  • TILs from 4 metastatic melanoma patients were isolated, cultured and expanded according to the clinical Rapid Expansion Protocol in the presence or absence of 50 nM PROS1 or aPROS1 mAb.
  • Total live cells were counted and fold expansion was calculated on day 16 and 23 of culture, relative to day 0.
  • Tumor biopsy material was digested and homogenized and equal“tumor soups” were put in culture in normal media, media plus Prosl , and media with blocking of Prosl (aPros).
  • Outgrowth of T cells was given as fold expansion, showing a clear trend towards limited outgrowth when prosl was blocked, and possibly a positive impact when Prosl was added.
  • MERTK expression was analysed on three-day activated CD8+ T cells which were co-stained with subset markers CCR7 and CD45R0. MERTK expression was significantly higher expressed on TCM CD8+ T cells. The results are shown in fig. 5.
  • Example 5 PROS1 co-stimulation on CD8+ T cells acts via MERTK
  • CD3/CD28 human PBMCs were activated with a pool of 23 peptides derived from cytomegalovirus, Epstein-Barr virus and influenza.
  • CD137 recently TCR- activated, naturally occurring, CD8+ T cells can be accurately identified .
  • CD3/CD28-activation The results are shown in fig. 6. Additionally, we found that resting or activated CD8+ T cells expressed only low levels of TYRO3 and do not express AXL (data not shown).
  • Example 6 PROS1 induces CD8+ T cell cytokine production.
  • Human CD8+ T cells were cultured in serum-free medium and activated for 3 days with aCD3/CD28 in the presence or absence of 50 nM PROS1. Chemokine CXCL10 and memory IL-7 production was measured in culture supernatants.
  • Example 7 PROS1 co-stimulation on CD8+ T cells acts via MERTK.
  • MERTK signaling in activated CD8+ T cells was inhibited.
  • siRNA-mediated knockdown of MERTK As our earlier results have shown that resting T cells do not express MERTK, CD8+ T cells were activated for three days prior to siRNA electroporation. We confirmed that siRNA knockdown resulted in a 70% reduction in MERTK protein levels compared to control. When re-activated, MERTK- knockdown cells produced less IFN-g. Moreover, IL-7, but not IL-15, secretion was significantly decreased.
  • MERTK inhibition significantly decreased aCD3/CD28-mediated CD8+ T cell proliferation, while no decrease in cell viability was seen.
  • MERTK inhibition could reverse the positive effects of PROS1 on IFN-g secretion. The results are shown in fig. 8.
  • the metabolism of activated CD8+ T cells in the presence or absence of PROS1- MERTK signalling was investigated. Bioenergetic phenotypes are shown to be strongly predictive for CD8+ T cell differentiation into the various memory subsets. Strikingly, the basal respiration rate of PROS1 -blocked cells was significantly decreased to 35% of control-stimulated cells. Accordingly, the ATP turnover of PROS1 -blocked cells was reduced to 31 %. Finally, the reserve respiratory capacity (SRC) of PROS1 -blocked cells was significantly decreased. This contrasts with activated CD8+ T cells supplemented with PROS1 , where no significant changes were found.
  • SRC reserve respiratory capacity
  • the gene encoding the transcription factor IRF4 was downregulated in PROS1-blocked cells versus control (Fig. 1 1 ). IRF4 has previously been correlated with metabolic programming of CD8+ T cells where it induces a metabolic shift, essential for antigen- specific responses and effector differentiation and function
  • Example 12 PROS1 -MERTK signaling affects melanoma TIL outgrowth and functionality
  • PROS1 -supplementation increased TIL-mediated killing in stepwise increments dependent on PROS1 levels (Fig. 12D). Cytokine secretion by T cells was inhibited at low levels of PROS1 as shown in the co-culture experiments, supposedly due to ligand competition (Fig. 12B).
  • PROS1 surface staining was party reversible by blockage of PtdSer ( Figure 13).
  • activated CD8+ T cells significantly increased TAM receptor MERTK surface expression from day two onwards, only on PROS1 -positive cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode pour améliorer l'efficacité clinique d'une thérapie adoptive par lymphocytes T avec un ligand de MerTK. L'invention concerne en outre un ligand de MerTK destiné à être utilisé dans le traitement d'un cancer chez un individu, ledit procédé comprenant la thérapie adoptive par lymphocytes T.
PCT/EP2019/059877 2018-04-19 2019-04-17 Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t WO2019201970A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18168195 2018-04-19
EP18168195.8 2018-04-19
EP18210051 2018-12-04
EP18210051.1 2018-12-04

Publications (1)

Publication Number Publication Date
WO2019201970A1 true WO2019201970A1 (fr) 2019-10-24

Family

ID=66165983

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2019/059877 WO2019201970A1 (fr) 2018-04-19 2019-04-17 Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t

Country Status (1)

Country Link
WO (1) WO2019201970A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032634A1 (fr) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University Methode de production de cellule tueuse naturelle mature
WO2016106221A1 (fr) 2014-12-22 2016-06-30 The Rockefeller University Anticorps agonistes anti-mertk et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007032634A1 (fr) * 2005-09-12 2007-03-22 Industry Foundation Of Chonnam National University Methode de production de cellule tueuse naturelle mature
WO2016106221A1 (fr) 2014-12-22 2016-06-30 The Rockefeller University Anticorps agonistes anti-mertk et leurs utilisations

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, R.; M. DONIA; E. ELLEBAEK; T. HOLZ BORCH; P. KONGSTED; T. Z. IVERSEN; L. ROSENKRANTZ HOLMICH; H. WESTERGREN HENDEL; O. M: "Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen", CLINICAL CANCER RESEARCH, vol. 22, 2016, pages 3734 - 3745
CABEZON ET AL.: "MERTK as negative regulator of human T cell activation", J. LEUKOCYTE BIOLOGY, vol. 97, no. 4, 2015, pages 751 - 760
CABEZÓN RAQUEL ET AL: "MERTK as negative regulator of human T cell activation.", JOURNAL OF LEUKOCYTE BIOLOGY APR 2015, vol. 97, no. 4, April 2015 (2015-04-01), pages 751 - 760, XP002792069, ISSN: 1938-3673 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2012 (2012-02-01), MIGDALL-WILSON JUSTINE ET AL: "Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus", XP002792070, Database accession no. PREV201200408432 *
HÖLSKEN OLIVER ET AL: "Exploiting natural killer cells for therapy of melanoma.", JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT = JOURNAL OF THE GERMAN SOCIETY OF DERMATOLOGY : JDDG JAN 2015, vol. 13, no. 1, January 2015 (2015-01-01), pages 23 - 29, XP002792073, ISSN: 1610-0387 *
JUNE, C. H.: "Serial Killers and Mass Murderers: Engineered T Cells Are up to the Task", CANCER IMMUNOL. RES., vol. 3, 2015, pages 470 - 472
KASIKARA, C.; S. KUMAR; S. KIMANI; W. I. TSOU; K. GENG; V. DAVRA; G. SRIRAM; C. DEVOE; K. Q. NGUYEN; A. ANTES: "Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy", CLIN. CANCER RES., vol. 17, 2011, pages 4550 - 4557, XP055144006, DOI: doi:10.1158/1078-0432.CCR-11-0116
LIHUA E. BUDDE ET AL: "Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma", PLOS ONE, vol. 8, no. 12, 17 December 2013 (2013-12-17), pages e82742, XP055213511, DOI: 10.1371/journal.pone.0082742 *
MELIEF SARA M ET AL: "IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 66, no. 7, 11 April 2017 (2017-04-11), pages 913 - 926, XP036266764, ISSN: 0340-7004, [retrieved on 20170411], DOI: 10.1007/S00262-017-1995-X *
PLOS ONE, vol. 7, no. 2, February 2012 (2012-02-01), DOI: 10.1371/JOURNAL.PONE.0031635 *
RUVOLO PETER P ET AL: "Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms.", HAEMATOLOGICA 12 2017, vol. 102, no. 12, December 2017 (2017-12-01), pages 2048 - 2057, XP002792071, ISSN: 1592-8721 *
TRAN, E.; S. TURCOTTE; A. GROS; P. F. ROBBINS; Y. C. LU; M. E. DUDLEY; J. R. WUNDERLICH; R. P. SOMERVILLE; K. HOGAN; C. S. HINRICH: "Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer", SCIENCE, vol. 344, 2014, pages 641 - 645, XP055161464, DOI: doi:10.1126/science.1251102

Similar Documents

Publication Publication Date Title
JP7181917B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
JP7252383B2 (ja) 末梢血から腫瘍反応性t細胞の濃縮された集団を作製する方法
JP7451468B2 (ja) 非造血組織常在性γδ T細胞の増幅および該細胞の使用
JP7315435B2 (ja) 抗ヒトパピローマウイルス抗原t細胞の調製方法
US10653756B2 (en) Identification of CD8+ T cells that are CD161hi and/or IL18R(α)hi and have rapid drug efflux capacity
ES2643387T3 (es) Estirpe celular de linfocitos que comprende células gama-delta, composición y método de producción de la misma
Peeters et al. MERTK acts as a costimulatory receptor on human CD8+ T cells
WO2017048614A1 (fr) Procédés d'isolement de récepteurs de lymphocytes t réactifs à une tumeur à partir de tumeur ou de sang périphérique
US20220378826A1 (en) Tumour infiltrating lymphocyte therapy and uses thereof
EP3052085A1 (fr) Activation de cellules nkt médiée par des cellules présentatrices de l'antigène artificielles à base de nanoparticules
WO2020109616A1 (fr) Modification de lymphocytes t
JP2022543026A (ja) Nk細胞を評価するためのシステム及び方法
WO2011013129A1 (fr) Sélection de lymphocytes pour le traitement du cancer
WO2019201970A1 (fr) Ligand de mertk pour la thérapie adoptive anicancéreuse par lymphocytes t
WO2017176932A1 (fr) Méthodes de traitement du cancer et de maladies infectieuses à l'aide de thérapies à base de cellules
JP7014820B2 (ja) 胚性間葉系始原細胞の製造方法及び使用方法
Pan et al. Natural Killer Cells at the Forefront of Cancer Immunotherapy with Immune Potency, Genetic Engineering, and Nanotechnology
RU2808817C2 (ru) Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
Liu et al. IP-10 enhances the amplification capacity and antitumor activity of CAR-T cells in vitro and could influence positive outcomes in MM patients treated with CAR-T cell therapy
Jordan et al. AXL inhibition suppresses early allograft monocyte-to-macrophage differentiation and prolongs allograft survival
Heimann Elongated T cell expansion by utilizing IL7 and IL15 leads to increased T cell yield while preserving Tcm/Tscm characteristics feasible for adoptive T cell therapy
Schötterl Functional and therapeutic effects of viscumins in the treatment of experimental glioblastoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19717322

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19717322

Country of ref document: EP

Kind code of ref document: A1